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ABSTRACT 
 
In the present opinion article we highlight evidence from different laboratories to drive the attention of 
the scientific community on the role played by endo-lysosomal Two-Pore Channels (TPCs) in viral 
infection. In particular, cross linking of our recent data and existing literature, we focus on evidence 
indicating that virus intracellular pathway could be targeted by a novel occurring TPCs inhibitor, the 
flavonoid Naringenin. A conceptual framework is presented for considering such a strategy as a 
promising approach to limit the infection mediated by the novel coronavirus SARS-CoV-2. Our 
hypothesis offers a perspective on a novel molecular target, TPCs, which could be exploited for a 
pharmacological blockade of SARS-CoV-2 infectivity. 
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The Coronaviruses are emerging viruses that are able to cross the species barrier and cause severe 
diseases in humans. Two such recent events are the highly pathogenic Serious Acute Respiratory 
Syndrome-related CoV (SARS-CoV) that became apparent in Southern China in 2003 and Middle East 
Respiratory Syndrome-related CoV (MERS-CoV), which emerged in 2012. 
In the present dramatic outbreak of coronavirus disease-19 (COVID-19) that is caused by SARS-CoV-
2 (recently reviewed in [1]), while science and medicine are striving to develop efficient treatments, we 
urge researchers to take into serious consideration a novel pharmacological strategy, highly promising 
for efficient and safe prophylaxis and therapy. What we recommend is to focus on the role played by 
the endo-lysosomal two-pore channel family (TPCs) in viral infection and on the feasibility of blocking 
the intracellular pathway of the virus by inhibiting these channels. Cross-analysis of data published 
over different times, experimental models and approaches gives direct and indirect evidence in support 
of this proposal. 
 
First of all, Sakurai et al. [2] demonstrated that TPC2 is required for release of the Ebola viral genome 
into the host cell during Ebola virus entry pathway and, interestingly, TPC2 inhibitors such as 
tetrandrine have proven capable of blocking virus trafficking and prevented infection in vitro and in 
mice in vivo. Intriguingly, our recent evidence has shown that the activity of human TPC channels can 
be inhibited by a natural flavonoid compound, in fact present in citruses and tomatoes, Naringenin [3]. 
In our opinion this evidence gives priority to Naringenin (Nar) for testing as a safe potential weapon 
against the present infection. The rationale for a defence line based on inhibiting lysosomal pro-viral 
activity through TPC2 inhibition is further supported by the following direct and indirect data. It has 
been shown [4] that knockdown and pharmacological inhibitors of both TPC2, mainly expressed in late 
endosomes/lysosomes, and TPC1, which mainly localises to early endosomes, attenuate intracellular 
trafficking of coronavirus MERS-CoV through the endolysosomal system, even though the data were 
obtained using an  artificial virion. Besides TPC2, Nar is also an inhibitor of TPC1 activity with an 
IC50 of about 500 µM therefore larger than for TPC2 (about 200 µM) [3]. 
 
Relevant and very recent in vitro evidence has shed light to the efficacy of chloroquine to fight SARS-
CoV-2 infection through lysosomal alkalinization [5,6] . As a matter of fact, chloroquine acts as a weak 
base and accumulates in the lysosomes quenching their acidic pH, thereby halting autophagic 
degradative flux[7]. In line with this evidence, interestingly, it has been found that loss of TPC2 leads 
to an increase in melanosome/lysosome pH [8,9,10]. In fact, TPC2 was shown to be involved in the 
control of human melanosome luminal pH: actually in TPC2-KO human melanotic MNT-1 cells, and 
in primary melanocytes subjected to TPC2 knockout by the CRISPR/Cas9 gene editing system, the 
lumen of melanosomes is more alkaline than in control cells [8]. Bellono et al. [10] also hypothesized 
that TPC2 can regulate melanosome pH producing a cation counterflux to enhance V-ATPase H+ 
transport into the melanosome lumen, consistent with the requirement for an inward cation current in 
lysosomal acidification [11]. In addition, Cang et al. (2013) demonstrated a shift toward alkalinization 
in TPC2-/- macrophage lysosomes after starvation [9]. 
Since viral replication takes place in specific cellular compartments induced by viral proteins which 
modify cell organelles to create sites for replication, hidden from innate immunity, membrane fusion 
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mechanisms are crucial events in the infection process. To this purpose, the virus S protein consists of 
two subunits, S1 and S2, with S1 providing the receptor binding function through the entry receptor 
ACE2 and S2 providing fusion activity. Interestingly, the subunits are cleaved from the complete S by 
host cell proteases (cysteine proteases cathepsin B and L, furin proteases and cellular serine protease 
TMPRSS2) and following receptor binding by S1, the fusion mechanism of S2 acts to bring the viral 
and cellular vesicles membranes into such close proximity that fusion occurs (reviewed in [12]). In this 
context, it should be noted that the opening of TPCs induces a strong sodium-driven depolarization in 
the endo-lysosomal membrane [13,14], which is supposed to enhance membrane fusion mechanisms 
[13]. In line with this hypothesis, COS-1 cells transfected with human TPC2 have larger lysosomes 
than cells transfected with a non-functional form of the channel. Moreover, it was recently shown [15] 
that TPCs are directly involved in sodium efflux, which, in parallel with chloride movement, regulates 
osmolyte release in endocytic vacuoles, with significant modification of vacuolar surface-to-volume 
ratio. Therefore, inhibition of TPCs should impair both the fusogenic potential of the endo-lysosomal 
system and alter the normal trafficking, which, in turn, could be a limit for viral replication [12]. Very 
recently, unique features of TPC2 in the response to different agonists have been published [16] 
expanding the characterization of this channel,  hence the range of potential approaches to 
pharmacologically control the intracellular pathway of the virus.  
 
The use of Nar, one of the main flavonoids present in the human diet, as a specific inhibitor of TPCs 
[17] has several advantages. Nar is a hydrophobic molecule able to cross biological membranes and to 
reach the intracellular compartments (endosomes and lysosomes) where TPCs are localized. The 
toxicity of Nar is low: concentrations greater than 1 mM do not affect human hepatocytes viability [18] 
and, in mice, doses up to 1500 mg/kg given by intraperitoneal injection did not induce marked 
elevation of liver enzymes or cause animal death [18]. Interestingly, in the same study [18], Nar was 
shown to be effective to reduce Hepatitis C virus secretion by 80% when added at 200 µM in infected 
Huh7.5.1 human hepatoma cell line. Moreover, that Nar treatment could be a promising strategy to 
inhibit virus replication and infection is further confirmed by interesting studies on the influenza A 
virus, dengue virus and Zika virus [19,20,21]. Antiviral effect of some flavonoids and Nar through 
blocking viral proteases activity in different experimental models has been also reported [22,23,24,25]. 
Of note, Nar has been shown to ameliorate acute inflammation [26] as well as lung fibrosis [27], which 
could represent a therapeutic advantage. In particular, Zeng et al. demonstrated that Nar suppresses 
inflammatory cytokine production through both transcriptional and post-transcriptional mechanisms 
(by regulating lysosome function) resulting in the inhibition of TNF-α and IL-6 secretion by 
macrophages and T cells [26,28].  Clinical trials analyzing the therapeutic potential of Nar have been 
recently reviewed [29] and an important clinical trial on the pharmacokinetics and metabolism of Nar 
has just been reported, indicating the strong interest around this compound [30]. While this manuscript 
was under review, an article by Ou et al. [31] demonstrated that TPC2 is a key player for SARS-CoV-2 
entry in 293/hACE2 cells, consistent with our findings and further supporting our hypothesis. 
In conclusion, these considerations offer a perspective on specific molecular targets, TPCs, and 
underpin a role for Naringenin as pharmacological blockade of SARS-CoV-2 infectivity providing 
further support for exploration of TPCs inhibition as novel antiviral therapy. 
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